Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Oncology (Williston Park, N.Y.)
|
August 20, 2016
Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma
Christopher Melani, Mark Roschewski
Leukemia & Lymphoma
|
November 12, 2021
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure
Christopher Melani, Wyndham H Wilson
Best Practice & Research. Clinical Haematology
|
September 15, 2018
Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA
Christopher Melani, Wyndham H Wilson, Mark Roschewski
British Journal of Haematology
|
March 14, 2018
What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?
Christopher Melani, Wyndham H Wilson, Mark Roschewski
Haematologica
|
August 2, 2018
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams <i>et al.</i>
Christopher Melani, Mark Roschewski, Wyndham H Wilson
Hematological Oncology
|
June 13, 2019
Liquid biopsy in non-Hodgkin's lymphoma
Christopher Melani, Wyndham H Wilson, Mark Roschewski
Blood
|
February 29, 2020
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder
Christopher Melani, Elaine S Jaffe, Wyndham H Wilson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2022
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
Rahul Lakhotia, Christopher Melani, Mark Roschewski, et al.
Blood Advances
|
June 24, 2026
Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma
Max J Gordon, Hyoyoung Choo-Wosoba, Gonca Ozcan, et al.
Leukemia & Lymphoma
|
October 17, 2017
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
Joseph Roswarski, Mark Roschewski, Andrea Lucas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Oncology (Williston Park, N.Y.)
|
August 20, 2016
Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma
Christopher Melani, Mark Roschewski
Leukemia & Lymphoma
|
November 12, 2021
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure
Christopher Melani, Wyndham H Wilson
Best Practice & Research. Clinical Haematology
|
September 15, 2018
Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA
Christopher Melani, Wyndham H Wilson, Mark Roschewski
British Journal of Haematology
|
March 14, 2018
What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?
Christopher Melani, Wyndham H Wilson, Mark Roschewski
Haematologica
|
August 2, 2018
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams <i>et al.</i>
Christopher Melani, Mark Roschewski, Wyndham H Wilson
Hematological Oncology
|
June 13, 2019
Liquid biopsy in non-Hodgkin's lymphoma
Christopher Melani, Wyndham H Wilson, Mark Roschewski
Blood
|
February 29, 2020
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder
Christopher Melani, Elaine S Jaffe, Wyndham H Wilson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2022
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
Rahul Lakhotia, Christopher Melani, Mark Roschewski, et al.
Blood Advances
|
June 24, 2026
Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma
Max J Gordon, Hyoyoung Choo-Wosoba, Gonca Ozcan, et al.
Leukemia & Lymphoma
|
October 17, 2017
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
Joseph Roswarski, Mark Roschewski, Andrea Lucas, et al.
Page
of 3